Shopping Cart 0
Cart Subtotal
USD 0

Transforming Growth Factor Beta 1 (TGFB1)-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500

Details

Transforming Growth Factor Beta 1 (TGFB1)-Pipeline Review, H1 2017

Summary

Transforming Growth Factor Beta 1 (TGFB1)-Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Acute Pain, Atherosclerosis, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Chronic Pancreatitis Pain, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Inflammation, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Scar, Skin Inflammation, Solid Tumor and Squamous Cell Carcinoma.

The latest report Transforming Growth Factor Beta 1 (TGFB1)-Pipeline Review, H1 2017, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

The report reviews Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Transforming Growth Factor Beta 1 (TGFB1)-Overview

Transforming Growth Factor Beta 1 (TGFB1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transforming Growth Factor Beta 1 (TGFB1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transforming Growth Factor Beta 1 (TGFB1)-Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Eli Lilly and Company

Genzyme Corp

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Novartis AG

Scholar Rock Inc

Sirnaomics Inc

Transforming Growth Factor Beta 1 (TGFB1)-Drug Profiles

ACE-1332-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit TGF-Beta 1 for Osteoarthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fresolimumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta 1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulodexide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-089-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transforming Growth Factor Beta 1 (TGFB1)-Dormant Products

Transforming Growth Factor Beta 1 (TGFB1)-Discontinued Products

Transforming Growth Factor Beta 1 (TGFB1)-Product Development Milestones

Featured News & Press Releases

May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFb1 Latent Complex

Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US

Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA

Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field

Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705

Mar 27, 2008: Keryx Biopharmaceuticals Announces Termination Of SUN-MACRO Phase 4 Trial

Mar 07, 2008: Keryx Biopharmaceuticals Announces That SUN-MICRO Phase 3 Clinical Trial Fails To Meet Primary Efficacy Endpoint

Feb 11, 2008: Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

Nov 14, 2007: Keryx Announces Positive Final Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For The Treatment Of Diabetic Nephropathy

Oct 24, 2007: Keryx Biopharmaceuticals, Inc, Announces Final Phase II Data Presentation On KRX-101 At The Upcoming American Society Of Nephrology Renal Week

Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 And Phase 4 Clinical Program Of KRX-101 For Treatment Of Diabetic Nephropathy

May 06, 2007: Keryx Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Acceleron Pharma Inc, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by Genzyme Corp, H1 2017

Pipeline by Huabo Biopharm Co Ltd, H1 2017

Pipeline by Isarna Therapeutics GmbH, H1 2017

Pipeline by Johnson & Johnson, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Scholar Rock Inc, H1 2017

Pipeline by Sirnaomics Inc, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Dormant Products, H1 2017 (Contd..2), H1 2017

Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Acceleron Pharma Inc, Eli Lilly and Company, Genzyme Corp, Huabo Biopharm Co Ltd, Isarna Therapeutics GmbH, Johnson & Johnson, Novartis AG, Scholar Rock Inc, Sirnaomics Inc

Company Profile

Company Profile Title

Transforming Growth Factor Beta 1 (TGFB1)-Pipeline Review, H1 2017

Summary

Transforming Growth Factor Beta 1 (TGFB1)-Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Cardiovascular, Central Nervous System, Genetic Disorders and Respiratory which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Acute Pain, Atherosclerosis, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Chronic Pancreatitis Pain, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Inflammation, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Scar, Skin Inflammation, Solid Tumor and Squamous Cell Carcinoma.

The latest report Transforming Growth Factor Beta 1 (TGFB1)-Pipeline Review, H1 2017, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

The report reviews Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transforming Growth Factor Beta 1 (TGFB1)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Transforming Growth Factor Beta 1 (TGFB1)-Overview

Transforming Growth Factor Beta 1 (TGFB1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transforming Growth Factor Beta 1 (TGFB1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transforming Growth Factor Beta 1 (TGFB1)-Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Eli Lilly and Company

Genzyme Corp

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Novartis AG

Scholar Rock Inc

Sirnaomics Inc

Transforming Growth Factor Beta 1 (TGFB1)-Drug Profiles

ACE-1332-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit TGF-Beta 1 for Osteoarthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fresolimumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta 1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulodexide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-089-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transforming Growth Factor Beta 1 (TGFB1)-Dormant Products

Transforming Growth Factor Beta 1 (TGFB1)-Discontinued Products

Transforming Growth Factor Beta 1 (TGFB1)-Product Development Milestones

Featured News & Press Releases

May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFb1 Latent Complex

Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US

Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA

Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field

Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705

Mar 27, 2008: Keryx Biopharmaceuticals Announces Termination Of SUN-MACRO Phase 4 Trial

Mar 07, 2008: Keryx Biopharmaceuticals Announces That SUN-MICRO Phase 3 Clinical Trial Fails To Meet Primary Efficacy Endpoint

Feb 11, 2008: Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

Nov 14, 2007: Keryx Announces Positive Final Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For The Treatment Of Diabetic Nephropathy

Oct 24, 2007: Keryx Biopharmaceuticals, Inc, Announces Final Phase II Data Presentation On KRX-101 At The Upcoming American Society Of Nephrology Renal Week

Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 And Phase 4 Clinical Program Of KRX-101 For Treatment Of Diabetic Nephropathy

May 06, 2007: Keryx Announces Positive Interim Results From Phase 2 Clinical Study For KRX-101 (Sulodexide Gelcaps) For Treatment Of Diabetic Nephropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Acceleron Pharma Inc, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by Genzyme Corp, H1 2017

Pipeline by Huabo Biopharm Co Ltd, H1 2017

Pipeline by Isarna Therapeutics GmbH, H1 2017

Pipeline by Johnson & Johnson, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Scholar Rock Inc, H1 2017

Pipeline by Sirnaomics Inc, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Dormant Products, H1 2017 (Contd..2), H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Acceleron Pharma Inc, Eli Lilly and Company, Genzyme Corp, Huabo Biopharm Co Ltd, Isarna Therapeutics GmbH, Johnson & Johnson, Novartis AG, Scholar Rock Inc, Sirnaomics Inc